Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer
J. Clin. Invest. Ahmed Boucharaba, et al. 114:1714 doi:10.1172/JCI22123 [Go to this article.]

Figure 6
Effect of breast tumor cells on platelet aggregation and the release of LPA from activated platelets. (A) Indicated tumor cells previously cultured in the absence or presence of doxycycline were added to washed human platelets under stirring conditions. Platelet aggregation was recorded over the time as the percentage of light transmission. (B) Clone no. 3 cells were plated without or with doxycycline and stimulated with DMEM, LPA (10^–7 M) or MDA-BO2–induced platelet aggregation supernatants (Sup. aggreg.), in the presence or absence of PLB. Cell proliferation was measured as described in the legend of Figure 3. Data are expressed as the mean ± SD of 6 replicates and are representative of 3 separate experiments. ^#P < 0.0001, stimulated versus control cells.